OTCMKTS:CNTMF - Cansortium Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.20
  • Forecasted Upside: 18.81 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.01
▲ +0.03 (3.06%)
1 month | 3 months | 12 months
Get New Cansortium Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNTMF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNTMF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$1.20
▲ +18.81% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Cansortium in the last 3 months. The average price target is $1.20, with a high forecast of $1.20 and a low forecast of $1.20. The average price target represents a 18.81% upside from the last price of $1.01.
Buy
The current consensus among 1 investment analysts is to buy stock in Cansortium.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
1/29/2021Canaccord GenuityReiterated RatingBuy$1.20
i
6/3/2020Canaccord GenuityReiterated RatingBuy$0.70
i
6/28/2019Canaccord GenuityInitiated CoverageBuy
i
(Data available from 4/18/2016 forward)
Cansortium logo
Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in the United States. It operates cultivation, processing, and dispensary facilities in Florida and Texas; and a dispensary license in Pennsylvania. The company offers its products in the form of oral drops, capsules, suppositories, topicals, syringes, dried flowers, prerolls, and cartridges. It markets its products under the Fluent brand name. As of December 21, 2020, it operated 24 dispensaries. Cansortium Inc. was founded in 2015 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $1.01
$0.95
$1.06

50 Day Range

MA: $0.77
$0.66
$0.98

52 Week Range

Now: $1.01
$0.14
$0.99

Volume

152,765 shs

Average Volume

393,950 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cansortium?

The following equities research analysts have issued stock ratings on Cansortium in the last year: Canaccord Genuity.
View the latest analyst ratings for CNTMF.

What is the current price target for Cansortium?

1 Wall Street analysts have set twelve-month price targets for Cansortium in the last year. Their average twelve-month price target is $1.20, suggesting a possible upside of 18.8%. Canaccord Genuity has the highest price target set, predicting CNTMF will reach $1.20 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $1.20 for Cansortium in the next year.
View the latest price targets for CNTMF.

What is the current consensus analyst rating for Cansortium?

Cansortium currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CNTMF will outperform the market and that investors should add to their positions of Cansortium.
View the latest ratings for CNTMF.

What other companies compete with Cansortium?

How do I contact Cansortium's investor relations team?

The company's listed phone number is 305-902-2720. The official website for Cansortium is www.cansortium.com.